CCL1 and cancer: As depicted in Figure 1J, VNS treatment resulted in a significant reduction of I-309/CCL1 and MDC/CCL22, which is in line with peripheral reduction of Tregs, since both have been described to regulate Treg recruitment in murine cancer models (51–55).